Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $3.55 to $3.90 for the period, compared to the consensus estimate of $3.34. The company issued revenue guidance of $915 million to $985 million, compared to the consensus […]